Boston 7: cost and payments to doctors
What Medicare Part D paid pharmacies for Boston 7, and the payments that named it as the associated device or medical supply under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Bausch & Lomb Americas Inc.?
Bausch & Lomb Americas Inc. reported the most payments naming Boston 7. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $24K
- Providers
- 14
- Transactions
- 14
- Average per transaction
- $1,700
The per-transaction average — $1,700 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 14 providers the average total is $1,700, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bausch & Lomb Americas Inc. | $23,797 | 100.0% |
Other products from Bausch & Lomb Americas Inc.
The company that reported the most payments naming Boston 7 also reports against these.
- MIEBO$12,555,869
- XIIDRA$9,922,924
- INFUSE$8,244,628
- VYZULTA$3,949,322
- VISUDYNE$2,770,836
- enVista MX60 IOL$2,741,800
- OPHTHALMIC INSTRUMENTS$2,674,412
- STELLARIS ELITE$1,582,540
- ZENLENS$1,159,018
- Crystalens Accommodating IOL (AT-52AO)$1,142,392